TALi Digital (ASX:TD1) - Managing Director, Glenn Smith
Managing Director, Glenn Smith
Source: TechInvest
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • TALi Digital (TD1) has announced a collaboration with the Duke Clinical Research Institute (DCRI)
  • The Duke Clinical Research Institute is part of the Duke University School of Medicine and is the world’s largest academic clinical research organisation
  • Together, they will conduct clinical research programs to evaluate TALi’s technology platforms, TALi Train and TALi Detect
  • These game-based platforms are focused on improving early childhood-aged children’s attention span and cognitive focus
  • The first collaboration project will begin this year
  • Company shares are up 3.85 per cent and are trading for 2.7 cents each

TALi Digital (TD1) will work with the Duke Clinical Research Institute (DCRI) to conduct clinical research programs to evaluate TALi’s technology platform.

The Duke Clinical Research Institute is part of the Duke University School of Medicine and is the world’s largest academic clinical research organisation.

“We are excited to work with the DCRI, which has a proven track record of designing innovative large-scale, longitudinal studies for cognitive disorders in paediatric populations,” TALi Managing Director Glenn Smith said.

TALi Digital, formerly called Novita Healthcare, is a leading health technology company with a focus on improving learning and cognitive skills for early childhood-aged children.

Its two main platforms, TALi Train and TALi Detect, are game-based platforms which test and improve a child’s attention span, maintain focus, prevent impulsive behaviour, avoid distractions and fidgeting, and improve learning at school.

This collaboration will collect international clinical evidence of the benefits of these platforms.

“We welcome the opportunity to develop clinical research studies that will expand the clinical evidence base for novel and innovative digital tools to identify and treat the symptoms of inattention at a young age,” Duke Professor in Psychiatry and Behavioral Sciences and DCRI Digital Health Solutions Co-Director Professor Scott Kollins said.

“Collaborations like the one with the DCRI demonstrate the potential for TALi to have a tremendous impact on the lives of children and their broader communities,” Scott added.

The first collaboration project will begin this year.

Company shares are up 3.85 per cent and are trading for 2.7 cents each at 1:35 pm AEST.

TD1 by the numbers
More From The Market Online
AI gen cancer cell

Immutep reports strong response rate from immunotherapies treating carcinomas

Immutep Ltd has reported a slew of positive results from a trial to assess a combination…
AI gen cancer cell

Telix jumps 11.6% as US government indicates proposed medicare changes won’t affect prostate cancer drug

Telix has announced its prostate cancer imaging drug Illuccix won't be negatively impacted by proposed changes…
Image of a researcher looking through a microscope

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

PYC Therapeutics Ltd has begun a new trial into the safety and efficacy of its VP-001…
Shoulder bones X ray.

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Orthocell (ASX:OCC) shares jumped close to 5% heading into afternoon trade as the company flagged record…